309 related articles for article (PubMed ID: 17400325)
1. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study.
Ekstedt M; Franzén LE; Mathiesen UL; Holmqvist M; Bodemar G; Kechagias S
J Hepatol; 2007 Jul; 47(1):135-41. PubMed ID: 17400325
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with NAFLD and elevated liver enzymes.
Ekstedt M; Franzén LE; Mathiesen UL; Thorelius L; Holmqvist M; Bodemar G; Kechagias S
Hepatology; 2006 Oct; 44(4):865-73. PubMed ID: 17006923
[TBL] [Abstract][Full Text] [Related]
3. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
4. Declining frequency of liver enzyme abnormalities with statins: experience from general practice in Jerusalem.
Kiderman A; Ben-Dov IZ; Glikberg F; Ackerman Z
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1002-5. PubMed ID: 18787468
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease and the statins treatment.
Dima A; Marinescu AG; Dima AC
Rom J Intern Med; 2012; 50(1):19-25. PubMed ID: 22788090
[TBL] [Abstract][Full Text] [Related]
6. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.
Fernández-Miranda C; Pérez-Carreras M; Colina F; López-Alonso G; Vargas C; Solís-Herruzo JA
Dig Liver Dis; 2008 Mar; 40(3):200-5. PubMed ID: 18261709
[TBL] [Abstract][Full Text] [Related]
7. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
8. Statins and hepatic steatosis: perspectives from the Dallas Heart Study.
Browning JD
Hepatology; 2006 Aug; 44(2):466-71. PubMed ID: 16871575
[TBL] [Abstract][Full Text] [Related]
9. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
Adams LA; Sanderson S; Lindor KD; Angulo P
J Hepatol; 2005 Jan; 42(1):132-8. PubMed ID: 15629518
[TBL] [Abstract][Full Text] [Related]
10. Liver enzymes and histology in obese patients with obstructive sleep apnea.
Kallwitz ER; Herdegen J; Madura J; Jakate S; Cotler SJ
J Clin Gastroenterol; 2007; 41(10):918-21. PubMed ID: 18090161
[TBL] [Abstract][Full Text] [Related]
11. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease.
Kantartzis K; Thamer C; Peter A; Machann J; Schick F; Schraml C; Königsrainer A; Königsrainer I; Kröber S; Niess A; Fritsche A; Häring HU; Stefan N
Gut; 2009 Sep; 58(9):1281-8. PubMed ID: 19074179
[TBL] [Abstract][Full Text] [Related]
12. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study.
Adams LA; Waters OR; Knuiman MW; Elliott RR; Olynyk JK
Am J Gastroenterol; 2009 Apr; 104(4):861-7. PubMed ID: 19293782
[TBL] [Abstract][Full Text] [Related]
13. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
[TBL] [Abstract][Full Text] [Related]
14. [Non-alcoholic fatty liver disease--new view].
Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
[TBL] [Abstract][Full Text] [Related]
15. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.
Wong VW; Wong GL; Tsang SW; Hui AY; Chan AW; Choi PC; Chim AM; Chu S; Chan FK; Sung JJ; Chan HL
Aliment Pharmacol Ther; 2009 Feb; 29(4):387-96. PubMed ID: 19035982
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
[TBL] [Abstract][Full Text] [Related]
17. Spectrum of histological features in non-alcoholic fatty liver disease.
Vasdev N; Kakati AG; Saigal S; Nayak NC
Natl Med J India; 2007; 20(6):282-7. PubMed ID: 18335793
[TBL] [Abstract][Full Text] [Related]
18. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?
Athyros VG; Tziomalos K; Daskalopoulos GN; Karagiannis A; Mikhailidis DP
Ann Med; 2011 May; 43(3):167-71. PubMed ID: 21476786
[TBL] [Abstract][Full Text] [Related]
19. The safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health Databases.
García-Rodríguez LA; González-Pérez A; Stang MR; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):953-61. PubMed ID: 18425987
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
